The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin

The epidemiology of invasive fungal infections is changing, with new populations at risk and the emergence of resistance caused by the selective pressure from increased usage of antifungal agents in prophylaxis, empiric therapy, and agriculture. Limited antifungal therapeutic options are further cha...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoenigl, Martin, Sprute, Rosanne, Egger, Matthias, Arastehfar, Amir, Cornely, Oliver A., Krause, Robert, Lass-Flörl, Cornelia, Prattes, Juergen, Spec, Andrej, Thompson, George R., Wiederhold, Nathan, Jenks, Jeffrey D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Leading Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8501344/
https://www.ncbi.nlm.nih.gov/pubmed/34626339
http://dx.doi.org/10.1007/s40265-021-01611-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8501344/
https://www.ncbi.nlm.nih.gov/pubmed/34626339
http://dx.doi.org/10.1007/s40265-021-01611-0

Ejemplares similares